The EU plans to update its 20-year-old pharmaceutical legislation early next year to improve access to medicines and to make innovation more affordable. The introduction of biosimilar medicines was one of the pioneering and most successful reforms of the previous legislation in 2004. Now we need to update the legislation to make it fit for the future.